Summary of findings 3. Infliximab compared with placebo for hidradenitis suppurativa.

Infliximab compared with placebo for hidradenitis suppurativa
Patient or population: participants with hidradenitis suppurativa Settings: hospital‐based Intervention: infliximab Comparison: placebo
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Placebo	Infliximab
At least 50% decrease in HS Severity Index Follow‐up: 8 weeks	Study population		RR 4.80 (0.6 to 38.48)	33 (1 study)	⊕⊕⊕⊝ moderate¹	‐
	56 per 1000	267 per 1000 (33 to 1000)
	Moderate
	56 per 1000	269 per 1000 (34 to 1000)
Physician global assessment Follow‐up: 8 weeks	Study population		RR 4.80 (1.66 to 13.9)	33 (1 study)	⊕⊕⊕⊝ moderate¹	‐
	167 per 1000	800 per 1000 (277 to 1000)
	Moderate
	167 per 1000	802 per 1000 (277 to 1000)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; HS: hidradenitis suppurativa; RR: risk ratio.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

¹Downgraded one level for imprecision due to a small number of events in only a single study.